Cardiovascular Disorders in Hemodialysis

14th International Course on Hemodialysis, Vicenza, May 2005

Editor(s): Ronco C. (Vicenza) 
Brendolan A. (Vicenza) 
Levin N.W. (New York, N.Y.) 
Table of Contents
Vol. 149, No. , 2005
Section title: Paper
Ronco C, Brendolan A, Levin NW (eds): Cardiovascular Disorders in Hemodialysis. Contrib Nephrol. Basel, Karger, 2005, vol 149, pp 69-82

What Did We Learn from the HEMO Study? Implications of Secondary Analyses

Greene T.
Department of Biostatistics and Epidemiology, Cleveland Clinic Foundation, Cleveland, Ohio, USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: The HEMO Study was a randomized clinical trial designed to determine whether increasing hemodialysis dose above current standards, or using high-flux membranes, would improve patient outcome. The primary results of the trial showed no statistically significant effects of either dialysis dose or membrane flux on the primary outcome of mortality. Methods: This report examines the implications of secondary analyses involving subgroups and secondary outcome measures for the overall interpretation of the trial. Results and Conclusions: The secondary analyses of the HEMO Study do not alter the conclusions of the primary analysis: In the context of conventional three times per week hemodialysis, neither the high-flux nor high-dose interventions substantially improved patient outcome compared to low-flux and standard-dose levels. However, certain secondary results from the trial are consistent with the hypothesis of subtle effects that may be magnified by more intensive therapies that extend beyond the limits of conventional three times per week dialysis. This hypothesis will be addressed by a pair of new randomized trials sponsored by the National Institute of Digestive and Kidney Disease (NIDDK), which will compare six times per week daily and nocturnal therapies with conventional three times per week dialysis.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00